These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6164559)

  • 21. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First clinical experiences with a selective chemotherapy of hepatocellular carcinoma with 5-fluorouridine in combination with other antipyrimidines.
    Pausch J; Holstege A; Anukarahanonta T; Keppler D; Gerok W
    Adv Enzyme Regul; 1985; 24():429-34. PubMed ID: 2424285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC
    Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract]   [Full Text] [Related]  

  • 24. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD; Smith PA; Levy EJ; Handschumacher RE
    Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II evaluation of PALA in patients with advanced head and neck cancer.
    Creagan ET; Nichols WC; O'Fallon JR
    Cancer Treat Rep; 1981; 65(9-10):827-9. PubMed ID: 7273014
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase I trial of N-(phosphonacetyl)-L-aspartate.
    Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
    Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of tyrosine aminotransferase induction by UTP deficiency and its reversal by 5-fluorouridine in cultured hepatoma cells.
    Giesen EM; Beck G; Holstege A; Keppler DO
    Biochim Biophys Acta; 1981 Aug; 655(1):34-40. PubMed ID: 6167286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme pattern-directed chemotherapy. Effects of antipyrimidine combinations on the ribonucleotide content of hepatomas.
    Lui MS; Jackson RC; Weber G
    Biochem Pharmacol; 1979 Apr; 28(7):1189-95. PubMed ID: 444276
    [No Abstract]   [Full Text] [Related]  

  • 30. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of PALA in advanced large bowel carcinoma.
    Rubin J; Purvis J; Britell JC; Hahn RG; Moertel CG; Schutt AJ
    Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Nichols WC; Ingle JN; Kvols LK
    Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract]   [Full Text] [Related]  

  • 33. Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars.
    Peters GJ; Laurensse E; Lankelma J; Leyva A; Pinedo HM
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1425-31. PubMed ID: 6542012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uridine triphosphate deficiency, growth inhibition, and death in ascites hepatoma cells induced by a combination of pyrimidine biosynthesis inhibition with uridylate trapping.
    Keppler DO
    Cancer Res; 1977 Mar; 37(3):911-7. PubMed ID: 189918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
    Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
    [No Abstract]   [Full Text] [Related]  

  • 36. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of the activity of PALA by dipyridamole.
    Chan TC; Young B; King ME; Taetle R; Howell SB
    Cancer Treat Rep; 1985 Apr; 69(4):425-30. PubMed ID: 3857969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
    Kensler TW; Reck LJ; Cooney DA
    Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.